EQS-Adhoc 101 0 Kommentare MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year

Für Sie zusammengefasst

MeVis Medical Solutions AG is adjusting its annual forecast for the current fiscal year based on preliminary business figures for the first ten months.
Due to current project developments and subdued expectations in new projects, the company expects its revenue performance to be more cautious than before.
Revenues for fiscal year 2022/2023 are now expected to decline to between €17.0 million and €17.5 million, compared to the previous forecast of stable revenues of €18.0 million to €18.5 million.
EBIT is expected to be in a range of €3.5 million to €4.0 million, compared to the previous forecast of a decline to €4.5 million to €5.0 million. The development of the US dollar/euro exchange rate has also impacted earnings.

EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Change in Forecast
MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year

31-Jul-2023 / 16:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Bremen, July 31, 2023 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its annual forecast for the current fiscal year based on the preliminary business figures for the first ten months.

In light of a challenging macroeconomic environment with accelerating inflation and the ongoing war in Ukraine, MeVis Medical Solutions AG sees its revenue performance more cautious than before due to current project developments and subdued expectations in new projects. For fiscal year 2022/2023 (October 1, 2022 to September 30, 2023), revenues are now expected to decline to between € 17.0 million and € 17.5 million (previous forecast: stable revenues of € 18.0 million to € 18.5 million). EBIT (earnings before interest and taxes) is expected to be in a range of € 3.5 million to € 4.0 million in fiscal 2022/2023 in view of the changed assumptions (previous forecast: decline to € 4.5 million to € 5.0 million). In addition, earnings have been strongly impacted by the development of the US dollar/euro exchange rate since the beginning of the fiscal year.

Contact:

Kirchhoff, Marcus / CEO

End of Inside Information

31-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	MeVis Medical Solutions AG
	Caroline-Herschel-Str. 1
	28359 Bremen
	Germany
Phone:	+49 421 224 95 0
Fax:	+49 421 224 95 999
E-mail:	ir@mevis.de
Internet:	http://www.mevis.de
ISIN:	DE000A0LBFE4
WKN:	A0LBFE
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1692327